SCHEMBL14633247

SCHEMBL14633247

CC(C)(C)OC(=O)NCCn1ccc(C=O)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.41
ALDH1A1 P00352 1/20 0.40
GFER P55789 1/20 0.40
MALT1 Q9UDY8 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
BCHE P06276 1/20 0.38
PIM1 P11309 1/20 0.38
PIM3 Q86V86 1/20 0.38
CCNC P24863 1/20 0.38
CDK8 P49336 1/20 0.38
BRD4 O60885 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
CKS1B P61024 1/20 0.37
SKP1 P63208 1/20 0.37
SKP2 Q13309 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1632156 0.85 NAMPT (0.44) DRD2ALDH1A1GFERMALT1TDP1
SCHEMBL2661800 0.82 DRD2 (0.43) DRD2ALDH1A1GFERMALT1TDP1
SCHEMBL1632152 0.82 DRD2 (0.43) DRD2ALDH1A1GFERMALT1TDP1
SCHEMBL18758224 0.80 HTT (0.43) DRD2ALDH1A1GFERMALT1TDP1
SCHEMBL18758312 0.80 LMNA (0.43) DRD2ALDH1A1GFERMALT1CCNC
SCHEMBL13011413 0.80 DRD2 (0.41) DRD2ALDH1A1GFERMALT1TDP1
SCHEMBL30872245 0.78 ADORA3 (0.41) DRD2ALDH1A1GFERMALT1CCNC
SCHEMBL17274051 0.78 PDE10A (0.49) DRD2MALT1BCHEBRD4CKS1B
SCHEMBL10264585 0.78 LMNA (0.46) DRD2ALDH1A1GFERBRD4CA12
SCHEMBL19344698 0.74 DRD2 (0.45) DRD2TDP1CCNCCDK8BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051327-B2 Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases ABBVIE INC. (US) 2015-06-09 US disclosed
US-20140296220-A1 PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES ABBVIE INC (US) 2014-10-02 US disclosed
US-8796289-B2 Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases ABBVIE INC. (US) 2014-08-05 US disclosed
WO-2013013031-A1 PYRIDAZINO [4, 5 -D] PYRIMIDIN- (6H) -ONE INHIBITORS OF WEE - 1 KINASE ABBVIE INC. (US) 2013-01-24 WO disclosed
US-20130023523-A1 PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2013-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296220-A1 PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES WEE1, WEE2, CDK1 DRD2 3785/4885ALDH1A1 1308/4885GFER 3500/4885
US-20130023523-A1 PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES WEE1, WEE2, CDK1 DRD2 3785/4885ALDH1A1 1308/4885GFER 3500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.